AstraZeneca’s MedImmune unit has appointed Dr Anand Subramony as its new vice president of drug delivery and device development.
He joins the company’s biopharmaceutical development unit from Novartis, whose Institutes for Biomedical Research he previously worked for in Cambridge, Massachusetts.
While at Novartis Dr Subramony established and headed company’s novel delivery technologies and therapeutics group.
Prior to that he held leadership positions at Dr. Reddy’s Laboratories in Bridgewater, New Jersey and Johnson & Johnson/Alza Corporation in Mountain View, California.
Dr Subramony will bring to MedImmune experience that includes drug-device combination products and a further boost to its focus on biologics delivery and device development.